Share your videos with the world

Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel. Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients. To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea